MX351698B - Complejos que contienen estroncio administrados tópicamente para tratar dolor, prurito e inflamación. - Google Patents

Complejos que contienen estroncio administrados tópicamente para tratar dolor, prurito e inflamación.

Info

Publication number
MX351698B
MX351698B MX2014011382A MX2014011382A MX351698B MX 351698 B MX351698 B MX 351698B MX 2014011382 A MX2014011382 A MX 2014011382A MX 2014011382 A MX2014011382 A MX 2014011382A MX 351698 B MX351698 B MX 351698B
Authority
MX
Mexico
Prior art keywords
strontium
pruritis
inflammation
irritation
pain
Prior art date
Application number
MX2014011382A
Other languages
English (en)
Other versions
MX2014011382A (es
Inventor
Gary S Hahn
Original Assignee
Cosmederm Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmederm Bioscience Inc filed Critical Cosmederm Bioscience Inc
Publication of MX2014011382A publication Critical patent/MX2014011382A/es
Publication of MX351698B publication Critical patent/MX351698B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La presente descripción consiste en composiciones terapéuticamente activas que combinan estroncio con por lo menos una molécula adicional que aumenta la potencia terapéutica general de la combinación más allá de la potencia de cualquiera de los constituyentes separados; específicamente, las combinaciones descritas aquí realizan dos funciones importantes; (1) aumentan la capacidad del estroncio tópicamente aplicado para inhibir tanto la irritación sensoria aguda (por ejemplo, prurito y dolor), enrojecimiento, hinchazón e inflamación (definido colectivamente para propósitos de esta descripción, "irritación") y la irritación crónica que es característica de, y que contribuye al desarrollo y mantenimiento de las condiciones neuropáticas dolorosas o pruríticas; y (2) disminuyen las trayectorias activadas del estroncio que se sabe mejorar el desarrollo y el mantenimiento de las condiciones de dolor, prurito, y neuropá.cas.
MX2014011382A 2012-03-21 2013-03-15 Complejos que contienen estroncio administrados tópicamente para tratar dolor, prurito e inflamación. MX351698B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613923P 2012-03-21 2012-03-21
PCT/US2013/032608 WO2013142383A1 (en) 2012-03-21 2013-03-15 Topically administered strontium-containing complexes for treating pain, pruritis and inflammation

Publications (2)

Publication Number Publication Date
MX2014011382A MX2014011382A (es) 2015-04-17
MX351698B true MX351698B (es) 2017-10-24

Family

ID=49223278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011382A MX351698B (es) 2012-03-21 2013-03-15 Complejos que contienen estroncio administrados tópicamente para tratar dolor, prurito e inflamación.

Country Status (16)

Country Link
US (5) US9333185B2 (es)
EP (1) EP2827847B1 (es)
JP (1) JP6163633B2 (es)
KR (1) KR101729096B1 (es)
CN (1) CN104363901B (es)
AU (1) AU2013235345B2 (es)
BR (1) BR112014023473B1 (es)
CA (2) CA3026687A1 (es)
ES (1) ES2930524T3 (es)
HK (1) HK1204266A1 (es)
IL (1) IL234701B (es)
MX (1) MX351698B (es)
PH (1) PH12014502093A1 (es)
RU (1) RU2605279C2 (es)
SG (1) SG11201405866VA (es)
WO (1) WO2013142383A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351698B (es) * 2012-03-21 2017-10-24 Cosmederm Bioscience Inc Complejos que contienen estroncio administrados tópicamente para tratar dolor, prurito e inflamación.
WO2016130686A1 (en) * 2015-02-11 2016-08-18 Cosmederm Bioscience, Inc. Stable high concentration strontium compounds and formulations for topical application
WO2016141219A1 (en) * 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US20170049807A1 (en) * 2015-08-21 2017-02-23 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US20170157169A1 (en) * 2015-08-21 2017-06-08 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
KR101651605B1 (ko) * 2015-12-10 2016-08-26 대봉엘에스 주식회사 신규 페놀산류 유도체 화합물, 및 이의 용도
EP3284462B1 (en) * 2016-08-17 2022-08-03 Galleon Labs LLC Strontium based compositions and formulations for pain, pruritus, and inflammation
KR101782966B1 (ko) * 2017-03-14 2017-09-28 전북대학교산학협력단 가려움증의 예방 또는 치료용 조성물
US10559492B2 (en) 2017-11-15 2020-02-11 Taiwan Semiconductor Manufacturing Company, Ltd. Patterning methods for semiconductor devices and structures resulting therefrom
WO2020037114A1 (en) * 2018-08-17 2020-02-20 Galleon Labs Llc Compositions and methods for the modulation of cytokines
WO2020247961A1 (en) * 2019-06-07 2020-12-10 Advanced Delivery Labs Llc Compositions and methods for improving wellness

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB487094A (en) 1937-05-24 1938-06-15 Niro Atomizer As Improved method of producing milk powder preparations
US3833732A (en) * 1973-05-24 1974-09-03 Miles Lab Method of treating inflammation utilizing alkyl esters of gallic acid
US4477439A (en) 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
GB2180153A (en) 1985-09-10 1987-03-25 Rory Ltd Compositions containing acetylcysteine
US6051609A (en) 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5804203A (en) 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
FR2740341B1 (fr) 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
US6808716B2 (en) 1999-01-08 2004-10-26 Ruey J. Yu N-acetylamino acids, related N-acetyl compounds and their topical use
JP4723143B2 (ja) 1999-09-14 2011-07-13 テファ， インコーポレイテッド γ−ヒドロキシブチレートを含むポリマーおよびオリゴマーの治療的用途
NO20014746D0 (no) 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
JP3947149B2 (ja) * 2002-10-28 2007-07-18 高砂香料工業株式会社 消臭剤組成物
CA2517005A1 (en) 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
LT1791791T (lt) * 2004-09-27 2019-09-10 Special Water Patents B.V. Vandens valymo būdai ir kompozicijos
GB2423928B (en) * 2004-11-16 2008-04-09 Efflux Technology Inc Methods and compositions for treating pain
US20080096872A1 (en) 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
US20060236470A1 (en) 2005-03-29 2006-10-26 Sabnis Ram W Novelty compositions with color changing indicator
AR055070A1 (es) 2005-06-29 2007-08-01 Panacea Biotec Ltd Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso
US20070134232A1 (en) 2005-12-14 2007-06-14 Joel Studin Topical bite care composition
US8158608B2 (en) 2006-03-30 2012-04-17 Council Of Scientific And Industrial Research Bioactive fraction from Zingier officinale and a process for the preparation thereof
US20100099640A1 (en) * 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
US20100226987A1 (en) * 2007-06-28 2010-09-09 Capsutech Ltd. Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
NZ555022A (en) 2007-11-07 2010-09-30 Encoate Holdings Ltd Stabilisation of dried biological material with oil and biopolymer
US20110129433A1 (en) 2008-06-26 2011-06-02 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders
CA2787339A1 (en) * 2009-01-20 2011-08-12 Signum Biosciences, Inc. Anti-inflammatory complexes
JP2013525500A (ja) 2010-05-05 2013-06-20 ロレアル アクリル増粘剤を含有する化粧品用組成物
EP2508168A1 (en) 2011-04-06 2012-10-10 The Procter and Gamble Company Cosmetic composition comprising polymer comprising direct crosslinks
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
MX351698B (es) * 2012-03-21 2017-10-24 Cosmederm Bioscience Inc Complejos que contienen estroncio administrados tópicamente para tratar dolor, prurito e inflamación.
US9480704B2 (en) * 2012-03-21 2016-11-01 Cosmederm Bioscience, Inc. Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
US20160250253A1 (en) 2013-09-24 2016-09-01 Cosmederm Bioscience, Inc. Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus
WO2016090029A1 (en) 2014-12-05 2016-06-09 Briggs & Stratton Corporation Pressure washers including jet pumps
WO2016130686A1 (en) 2015-02-11 2016-08-18 Cosmederm Bioscience, Inc. Stable high concentration strontium compounds and formulations for topical application
WO2016141219A1 (en) 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US20170157169A1 (en) 2015-08-21 2017-06-08 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
US20170049807A1 (en) 2015-08-21 2017-02-23 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation

Also Published As

Publication number Publication date
RU2014142259A (ru) 2016-05-20
JP2015510943A (ja) 2015-04-13
EP2827847B1 (en) 2022-09-14
JP6163633B2 (ja) 2017-07-19
ES2930524T3 (es) 2022-12-14
US20210177888A1 (en) 2021-06-17
IL234701B (en) 2020-03-31
HK1204266A1 (en) 2015-11-13
AU2013235345A1 (en) 2014-10-09
CN104363901B (zh) 2017-03-22
EP2827847A4 (en) 2015-01-28
CA3026687A1 (en) 2013-09-26
PH12014502093A1 (en) 2014-11-24
KR20140138993A (ko) 2014-12-04
US10159693B2 (en) 2018-12-25
US10874689B2 (en) 2020-12-29
RU2605279C2 (ru) 2016-12-20
KR101729096B1 (ko) 2017-04-21
BR112014023473B1 (pt) 2022-08-30
AU2013235345B2 (en) 2016-03-24
US20150050361A1 (en) 2015-02-19
WO2013142383A1 (en) 2013-09-26
CN104363901A (zh) 2015-02-18
US11801261B2 (en) 2023-10-31
US20170020918A1 (en) 2017-01-26
CA2867439C (en) 2019-02-12
IL234701A0 (en) 2014-11-30
US9333185B2 (en) 2016-05-10
US20190076469A1 (en) 2019-03-14
EP2827847A1 (en) 2015-01-28
MX2014011382A (es) 2015-04-17
US20240041919A1 (en) 2024-02-08
BR112014023473A2 (es) 2017-06-20
CA2867439A1 (en) 2013-09-26
SG11201405866VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
PH12014502093A1 (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
PH12017502092A1 (en) Topical pharmaceutical compositions
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
PH12015500825B1 (en) Substituted benzene compounds
MX344530B (es) Compuestos de benceno substituido.
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
GB2476446A (en) Topical treatment of skin infection
EA201401031A1 (ru) Полутвёрдая композиция для местного применения, которая содержит пирфенидон и модифицированный диаллилдисульфид оксид (m-ddo) для удаления или предупреждения угрей
MX2021001276A (es) Composiciones de bismuto-tiol y metodos para tratar heridas.
MX368853B (es) Composiciones y métodos tópicos para el tratamiento de heridas.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2024006094A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
WO2015035410A8 (en) Cancer therapy
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições
WO2010023195A3 (en) Compositions and methods for treating cancer
WO2014160508A8 (en) Methods and compositions for treating cancer and inflammatory diseases
BR112014032169A2 (pt) tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa
TW201129361A (en) Methods for treating pain
BR112013000296A2 (pt) agentes terapêuticos 976
MX354614B (es) Composición farmacéutica de diosmina y hesperidina y su uso en dolor neuropático.
MX358072B (es) Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor.
BR112014015193A8 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico

Legal Events

Date Code Title Description
FG Grant or registration